Checkpoint Therap(CKPT.US)

Company Encyclopedia
View More
name
Checkpoint Therap
CKPT.US
Checkpoint Therapeutics, Inc., a commercial -stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company’s lead antibody product candidate is UNLOXCYT, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It also developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. It has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains, as well as collaboration with Dana-Farber Cancer Institute, Inc.
1.896 T
CKPT.USMarket value -Rank by Market Cap -/-

Financial Score

01/01/2026 Update
D
BiotechnologyIndustry
Industry Ranking0/400
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-1869.55%E
    • Profit Margin-137821.95%E
    • Gross Margin0.00%E
  • Growth ScoreD
    • Revenue YoY-39.71%E
    • Net Profit YoY-8.01%C
    • Total Assets YoY185.29%A
    • Net Assets YoY258.98%A
  • Cash ScoreD
    • Cash Flow Margin-0.07%D
    • OCF YoY-39.71%E
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreC
    • Gearing Ratio52.30%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Short Interest in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Drops By 22.1%

    Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) experienced a 22.1% drop in short interest in May, totaling 2,960,000 shares. Currently, 6.2% of its shares are sold short, with a days-to-cover ratio of 1.1 days. CEO James F. Oliviero III and CFO William Garrett Gray sold shares recently, reducing their ownership. Institutional investors hold 22% of the stock. The company's stock opened at $4.26, with a market cap of $370.71 million. Analysts have mixed ratings, with price targets ranging from $4.10 to $4.80.

    Market Beat·
    US
    CKPT
    0.00%
    Market Beat·
    US
    CKPT
    0.00%

    Sun Pharma Finalizes $416M Deal for Checkpoint Therapeutics, Inc. (CKPT)

    Sun Pharmaceutical Industries Ltd. has completed its $416 million acquisition of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT), enhancing its immuno-oncology portfolio. The deal includes purchasing shares at $4.10 each, with potential additional payments through contingent value rights. The acquisition is bolstered by Checkpoint's FDA-approved drug UNLOXCYT, aimed at treating advanced cutaneous squamous cell carcinoma. Sun Pharma's Chairman, Dilip Shanghvi, emphasized the strategic importance of this addition to their product lineup. The acquisition reflects confidence in Checkpoint's long-term assets, including UNLOXCYT and olafertinib.

    insidermonkey·
    US
    CKPT
    0.00%
    insidermonkey·
    US
    CKPT
    0.00%

    Checkpoint Therap | 10-Q: FY2025 Q1 EPS: USD -0.19

    LB filings·
    US
    CKPT
    0.00%
    LB filings·
    US
    CKPT
    0.00%

    Checkpoint Therap | 8-K: FY2025 Q1 EPS: USD -0.19

    LB filings·
    US
    CKPT
    0.00%
    LB filings·
    US
    CKPT
    0.00%

    Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates | CKPT Stock News

    Checkpoint Therapeutics reported its Q1 2025 financial results, highlighting a cash position of $33 million, up from $6.6 million in Q4 2024. R&D expenses decreased to $3.8 million, while G&A expenses rose to $7.4 million. The company posted a net loss of $11.2 million. Additionally, UNLOXCYT™ was approved by the FDA for advanced cutaneous squamous cell carcinoma, and a special stockholder meeting for a merger with Sun Pharma is scheduled for May 28, 2025, with a transaction value of up to $416 million.

    StockTitan·
    US
    CKPT
    0.00%
    StockTitan·
    US
    CKPT
    0.00%
    © 2026 Longbridge｜Disclaimer